Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Adverum Biotechnologies Inc. is currently overseeing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, indicating that each pending matter is being handled independently within the patent office. The busiest examiner, KONOPKA, CATHERINE ANNE, is assigned 1 pending office action. Because the total number of pending actions is 2 and there are 2 examiners, the workload is distributed with 1 action per examiner.
The involvement of 2 distinct art units for 2 pending actions suggests that the company's research in Biotechnology & Pharmaceuticals covers different specialized classifications. This structure requires the company to manage 2 separate prosecution tracks, each with its own examiner and administrative unit. Such a decentralized approach means that the outcome of 1 pending action is unlikely to directly influence the other. Practitioners can benefit from this variety, as it provides multiple points of engagement with the patent office for their current pharmaceutical and biotechnological filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
| NGUYEN, QUANG | 1 | 38.0% | +52.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554965 | METHODS OF TREATING OCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT | KONOPKA, CATHERINE ANNE | — |
| 18307256 | COMPOSITIONS AND METHODS FOR ENHANCED GENE EXPRESSION | NGUYEN, QUANG | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554965 | METHODS OF TREATING OCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT | KONOPKA, CATHERINE ANNE | 1635 | §103DP | Final Rejection | — | Pending | Oct 11, 2023 |
| 18307256 | COMPOSITIONS AND METHODS FOR ENHANCED GENE EXPRESSION | NGUYEN, QUANG | 1631 | §112 | Non-Final OA | — | Pending | Apr 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial